Non-small cell lung cancer

Clinical practice guidelines in oncology

David S. Ettinger, Wallace Akerley, Gerold Bepler, Matthew G. Blum, Andrew Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Todd L. Demmy, Apar Kishor P Ganti, Ramaswamy Govindan, Frederic W. Grannis, Thierry Jahan, Mohammad Jahanzeb, David H. Johnson, Anne Kessinger, Ritsuko Komaki, Feng Ming Kong, Mark G. Kris, Lee M. Krug & 15 others Quynh Thu Le, Inga T. Lennes, Renato Martins, Janis O'Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, George R. Simon, Scott J. Swanson, Douglas E. Wood, Stephen C. Yang

Research output: Contribution to journalArticle

427 Citations (Scopus)

Abstract

Lung cancer is the leading cause of cancer-related death in the United States. The primary risk factor for lung cancer is smoking, which accounts for more than 85% of all lung cancer-related deaths. Radon gas, a radioactive gas that is produced by the decay of radium 226, is the second leading cause of lung cancer. The decay of this isotope leads to the production of substances that emit alpha-particles, which may cause cell damage and therefore increase the potential for malignant transformation. Furthermore, data suggest that postmenopausal women who smoke or are former smokers should not undergo hormone replacement therapy, because it increases the risk for death from non-small cell lung cancer. Important changes in these NCCN Guidelines for 2010 include updates to the Principles of Surgical Therapy and Radiation Therapy, and the addition of a section on maintenance therapy for advanced or metastatic disease. In addition, recommendations for a number of chemotherapy regimens were modified, including the addition of erlotinib as a first-line treatment option for patients who are positive for the EGFR mutation, and staging was updated per the IASLC recommendations.

Original languageEnglish (US)
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume8
Issue number7
StatePublished - Jul 2010

Fingerprint

Practice Guidelines
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Gases
Alpha Particles
Radium
Radon
Hormone Replacement Therapy
Smoke
Isotopes
Radiotherapy
Therapeutics
Smoking
Guidelines
Drug Therapy
Mutation
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Ettinger, D. S., Akerley, W., Bepler, G., Blum, M. G., Chang, A., Cheney, R. T., ... Yang, S. C. (2010). Non-small cell lung cancer: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 8(7).

Non-small cell lung cancer : Clinical practice guidelines in oncology. / Ettinger, David S.; Akerley, Wallace; Bepler, Gerold; Blum, Matthew G.; Chang, Andrew; Cheney, Richard T.; Chirieac, Lucian R.; D'Amico, Thomas A.; Demmy, Todd L.; Ganti, Apar Kishor P; Govindan, Ramaswamy; Grannis, Frederic W.; Jahan, Thierry; Jahanzeb, Mohammad; Johnson, David H.; Kessinger, Anne; Komaki, Ritsuko; Kong, Feng Ming; Kris, Mark G.; Krug, Lee M.; Le, Quynh Thu; Lennes, Inga T.; Martins, Renato; O'Malley, Janis; Osarogiagbon, Raymond U.; Otterson, Gregory A.; Patel, Jyoti D.; Pisters, Katherine M.; Reckamp, Karen; Riely, Gregory J.; Rohren, Eric; Simon, George R.; Swanson, Scott J.; Wood, Douglas E.; Yang, Stephen C.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 8, No. 7, 07.2010.

Research output: Contribution to journalArticle

Ettinger, DS, Akerley, W, Bepler, G, Blum, MG, Chang, A, Cheney, RT, Chirieac, LR, D'Amico, TA, Demmy, TL, Ganti, AKP, Govindan, R, Grannis, FW, Jahan, T, Jahanzeb, M, Johnson, DH, Kessinger, A, Komaki, R, Kong, FM, Kris, MG, Krug, LM, Le, QT, Lennes, IT, Martins, R, O'Malley, J, Osarogiagbon, RU, Otterson, GA, Patel, JD, Pisters, KM, Reckamp, K, Riely, GJ, Rohren, E, Simon, GR, Swanson, SJ, Wood, DE & Yang, SC 2010, 'Non-small cell lung cancer: Clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 8, no. 7.
Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT et al. Non-small cell lung cancer: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2010 Jul;8(7).
Ettinger, David S. ; Akerley, Wallace ; Bepler, Gerold ; Blum, Matthew G. ; Chang, Andrew ; Cheney, Richard T. ; Chirieac, Lucian R. ; D'Amico, Thomas A. ; Demmy, Todd L. ; Ganti, Apar Kishor P ; Govindan, Ramaswamy ; Grannis, Frederic W. ; Jahan, Thierry ; Jahanzeb, Mohammad ; Johnson, David H. ; Kessinger, Anne ; Komaki, Ritsuko ; Kong, Feng Ming ; Kris, Mark G. ; Krug, Lee M. ; Le, Quynh Thu ; Lennes, Inga T. ; Martins, Renato ; O'Malley, Janis ; Osarogiagbon, Raymond U. ; Otterson, Gregory A. ; Patel, Jyoti D. ; Pisters, Katherine M. ; Reckamp, Karen ; Riely, Gregory J. ; Rohren, Eric ; Simon, George R. ; Swanson, Scott J. ; Wood, Douglas E. ; Yang, Stephen C. / Non-small cell lung cancer : Clinical practice guidelines in oncology. In: JNCCN Journal of the National Comprehensive Cancer Network. 2010 ; Vol. 8, No. 7.
@article{ea6d619585f440acaaf3783730abea8d,
title = "Non-small cell lung cancer: Clinical practice guidelines in oncology",
abstract = "Lung cancer is the leading cause of cancer-related death in the United States. The primary risk factor for lung cancer is smoking, which accounts for more than 85{\%} of all lung cancer-related deaths. Radon gas, a radioactive gas that is produced by the decay of radium 226, is the second leading cause of lung cancer. The decay of this isotope leads to the production of substances that emit alpha-particles, which may cause cell damage and therefore increase the potential for malignant transformation. Furthermore, data suggest that postmenopausal women who smoke or are former smokers should not undergo hormone replacement therapy, because it increases the risk for death from non-small cell lung cancer. Important changes in these NCCN Guidelines for 2010 include updates to the Principles of Surgical Therapy and Radiation Therapy, and the addition of a section on maintenance therapy for advanced or metastatic disease. In addition, recommendations for a number of chemotherapy regimens were modified, including the addition of erlotinib as a first-line treatment option for patients who are positive for the EGFR mutation, and staging was updated per the IASLC recommendations.",
author = "Ettinger, {David S.} and Wallace Akerley and Gerold Bepler and Blum, {Matthew G.} and Andrew Chang and Cheney, {Richard T.} and Chirieac, {Lucian R.} and D'Amico, {Thomas A.} and Demmy, {Todd L.} and Ganti, {Apar Kishor P} and Ramaswamy Govindan and Grannis, {Frederic W.} and Thierry Jahan and Mohammad Jahanzeb and Johnson, {David H.} and Anne Kessinger and Ritsuko Komaki and Kong, {Feng Ming} and Kris, {Mark G.} and Krug, {Lee M.} and Le, {Quynh Thu} and Lennes, {Inga T.} and Renato Martins and Janis O'Malley and Osarogiagbon, {Raymond U.} and Otterson, {Gregory A.} and Patel, {Jyoti D.} and Pisters, {Katherine M.} and Karen Reckamp and Riely, {Gregory J.} and Eric Rohren and Simon, {George R.} and Swanson, {Scott J.} and Wood, {Douglas E.} and Yang, {Stephen C.}",
year = "2010",
month = "7",
language = "English (US)",
volume = "8",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "7",

}

TY - JOUR

T1 - Non-small cell lung cancer

T2 - Clinical practice guidelines in oncology

AU - Ettinger, David S.

AU - Akerley, Wallace

AU - Bepler, Gerold

AU - Blum, Matthew G.

AU - Chang, Andrew

AU - Cheney, Richard T.

AU - Chirieac, Lucian R.

AU - D'Amico, Thomas A.

AU - Demmy, Todd L.

AU - Ganti, Apar Kishor P

AU - Govindan, Ramaswamy

AU - Grannis, Frederic W.

AU - Jahan, Thierry

AU - Jahanzeb, Mohammad

AU - Johnson, David H.

AU - Kessinger, Anne

AU - Komaki, Ritsuko

AU - Kong, Feng Ming

AU - Kris, Mark G.

AU - Krug, Lee M.

AU - Le, Quynh Thu

AU - Lennes, Inga T.

AU - Martins, Renato

AU - O'Malley, Janis

AU - Osarogiagbon, Raymond U.

AU - Otterson, Gregory A.

AU - Patel, Jyoti D.

AU - Pisters, Katherine M.

AU - Reckamp, Karen

AU - Riely, Gregory J.

AU - Rohren, Eric

AU - Simon, George R.

AU - Swanson, Scott J.

AU - Wood, Douglas E.

AU - Yang, Stephen C.

PY - 2010/7

Y1 - 2010/7

N2 - Lung cancer is the leading cause of cancer-related death in the United States. The primary risk factor for lung cancer is smoking, which accounts for more than 85% of all lung cancer-related deaths. Radon gas, a radioactive gas that is produced by the decay of radium 226, is the second leading cause of lung cancer. The decay of this isotope leads to the production of substances that emit alpha-particles, which may cause cell damage and therefore increase the potential for malignant transformation. Furthermore, data suggest that postmenopausal women who smoke or are former smokers should not undergo hormone replacement therapy, because it increases the risk for death from non-small cell lung cancer. Important changes in these NCCN Guidelines for 2010 include updates to the Principles of Surgical Therapy and Radiation Therapy, and the addition of a section on maintenance therapy for advanced or metastatic disease. In addition, recommendations for a number of chemotherapy regimens were modified, including the addition of erlotinib as a first-line treatment option for patients who are positive for the EGFR mutation, and staging was updated per the IASLC recommendations.

AB - Lung cancer is the leading cause of cancer-related death in the United States. The primary risk factor for lung cancer is smoking, which accounts for more than 85% of all lung cancer-related deaths. Radon gas, a radioactive gas that is produced by the decay of radium 226, is the second leading cause of lung cancer. The decay of this isotope leads to the production of substances that emit alpha-particles, which may cause cell damage and therefore increase the potential for malignant transformation. Furthermore, data suggest that postmenopausal women who smoke or are former smokers should not undergo hormone replacement therapy, because it increases the risk for death from non-small cell lung cancer. Important changes in these NCCN Guidelines for 2010 include updates to the Principles of Surgical Therapy and Radiation Therapy, and the addition of a section on maintenance therapy for advanced or metastatic disease. In addition, recommendations for a number of chemotherapy regimens were modified, including the addition of erlotinib as a first-line treatment option for patients who are positive for the EGFR mutation, and staging was updated per the IASLC recommendations.

UR - http://www.scopus.com/inward/record.url?scp=77955408842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955408842&partnerID=8YFLogxK

M3 - Article

VL - 8

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 7

ER -